Request Demo
Astria scratches dealmaking itch, paying Ichnos $15M to join eczema race led by Amgen, Sanofi
Phase 2AcquisitionLicense out/inPhase 3
Astria Therapeutics is years behind the front-runners in the eczema race.
Astria Therapeutics finally found a buyer for its OX40 eczemaeczemaam. Astria Therapeutics has taken the other side of the deal, paying $15 million upfront to secure a spot at the back of a race led by Amgen and Sanofi.
Ichnos Sciencesd Ichnos has been talking about parOX40 eczemaOX40ing its OX40 workAstria Therapeutics as it has existed, having made the program available (PDF) for out-licensing the year after it spun out of GlenAmgenin 20Sanofier the years it has sought a partner, Ichnos has seen Sanofi acquire an OX40 candidate in its $1.1 billion takeover of Kymab and Amgen pay Kyowa Kirin $400 million upfront to enter the space.
Now, Ichnos has lIchnosa deal—but failed to command the sort oOX40ices paid by those Big Pharmas. The structure of the agreement, which is worth $15 million upfront, $20 million in clinical milestonGlenmark285 million in regulatory and commercial paydays, Ichnosts Astria’Sanofierred asset.OX40KymabAmgenKyowa Kirin
WhileIchnoss wrapped up a phase 2 trial of its lead OX40-targeting candidate telazorlimab in 2021, that candidate barely gets a mention in Astria’s statement to disclose the deal. Astria is licensing the full OX40 portfolio, but its focus is on STAR-0310, a preclinAstriarogram that is forecast to enter human testing early in 2025.
The tiIchnos puts Astria years behind the front-runnOX40-targeting started setelazorlimabclinical trials of its candidate, rocatinlimab, ovAstria past 16 months, while Sanofi top-lAstriaositive phase 2b data iOX40ne. In contrast, the first cliniSTAR-0310on STAR-0310 in healthy volunteers aren't expected until the third quarter of 2025, by which time Amgen could have phase 3 data on rocatinlimab.
Astria’s decision to focus on a preclinical program, rathAmgenan push telazorlimab into late-phase studies, could give it arocatinlimabted candidate. The biotech sees SSanofi10 as a best-in-class prospect, pointing to its use of half-life extension technoloSTAR-0310 could reduce dosing frequency, and early evidence of affinity, safety and tolerabilitAmgenmake its case.rocatinlimab
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.